Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Leukemia, Myeloid, Acute 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Myelodysplastic Syndromes 52Recurrence 37Leukemia, Lymphocytic, Chronic, B-Cell 37Multiple Myeloma 36Lymphoma, Non-Hodgkin 35Lymphoma 34Lymphoma, B-Cell 29Hematologic Neoplasms 28Lymphoma, Follicular 24Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Mantle-Cell 22Leukemia 22Melanoma 21Lymphoma, B-Cell, Marginal Zone 20Myeloproliferative Disorders 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Biphenotypic, Acute 18Hodgkin Disease 18Ovarian Neoplasms 17Burkitt Lymphoma 17Pancreatic Neoplasms 16Neoplasms 13Neoplasm Metastasis 12Leukemia, Myelomonocytic, Chronic 12Colorectal Neoplasms 11Anemia, Refractory, with Excess of Blasts 11Stomach Neoplasms 10Carcinoma, Non-Small-Cell Lung 10

Interventions

Cyclophosphamide 3fludarabine 2selinexor 1pembrolizumab 1pazopanib 1palbociclib 1mirdametinib 1fludarabine phosphate 1X-Rays 1Trabectedin 1Specimen Handling 1Radiation 1Proton Therapy 1Pioglitazone 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Ifosfamide 1Doxorubicin 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Liposarcoma, Myxoid × fludarabine × 1 year × Clear all
NCT03967223 2026-04-17

IGNYTE-ESO

USWM, LLC (dba US WorldMeds)

Phase 2 Active not recruiting
103 enrolled
Sarcoma

Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT06083883 2026-04-16

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

M.D. Anderson Cancer Center

Phase 1 Recruiting
44 enrolled
Sarcoma

Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡